Cox proportional hazard model to test the significance of clinical covariates and genotypes of the CYP11B2 polymorphism as predictors of renal survival within groups for each gender
| Variable | p value | HR | 95% CI |
|---|---|---|---|
| HR, hazard ratio; CI, confidence interval; ACEI/ARB, angiotensin-I converting enzyme inhibitor and/or angiotensin receptor blocker. | |||
| Female patients (n=143) | |||
| Urinary protein excretion >1.0 g/day | 0.0141 | 2.505 | 1.203 to 5.217 |
| Hypertension | 0.0073 | 1.918 | 1.259 to 3.942 |
| No ACEI/ARB administration | 0.0074 | 3.225 | 1.368 to 7.599 |
| CC genotype of CYP11B2 | 0.0022 | 4.284 | 1.686 to 10.881 |
| Male patients (n=128) | |||
| Urinary protein excretion >1.0 g/day | 0.0036 | 4.768 | 1.664 to 13.666 |
| Hypertension | 0.0007 | 3.649 | 1.725 to 7.718 |
| No ACEI/ARB administration | 0.0214 | 2.299 | 1.131 to 4.672 |
| CC genotype of CYP11B2 | 0.6269 | 0.788 | 0.301 to 2.061 |